Patents
Literature
33results about How to "Enhances intestinal epithelial barrier function" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmaceutical composition of nanoparticles
InactiveUS8257740B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPharmaceutical non-active ingredientsNanoparticleMedicine
The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial ermeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8535640B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleSurface charges
The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8361439B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8048404B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7998458B2Reduce resistanceEasy to transportIn-vivo radioactive preparationsPeptide/protein ingredientsMedicineNanoparticle
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS20120003306A1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryBiocideActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8202839B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8337811B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS7993625B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsNanoparticleMedicine
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a pegylated bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8354094B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7910086B1Reduce inflammatory responseEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsDrug deliveryActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7919072B1Reduce inflammationEnhances intestinal epithelial barrier functionIn-vivo radioactive preparationsPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses the bioactive nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8202508B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityIn-vivo radioactive preparationsPeptide/protein ingredientsActive agentSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8048453B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS20110142927A1Reduce resistanceEasy to transportPeptide/protein ingredientsPharmaceutical non-active ingredientsMedicineActive agent
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8119102B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8287905B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPeptide/protein ingredientsEpithelial permeabilityMedicine
The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7988949B2Reduce resistanceEasy to transportNervous disorderIn-vivo radioactive preparationsNanoparticleMedicine
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7863259B1Reduce resistanceEasy to transportBiocidePeptide/protein ingredientsMedicineNanoparticle
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7901666B1Reduce resistanceEasy to transportIn-vivo radioactive preparationsPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses a pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering the bioactive nanoparticles to the subject, wherein a first and a second bioactive nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains negatively charged substrate, and at least a first bioactive agent in the first nanoparticle and a second bioactive agent in the second nanoparticle.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS8188042B1Reduce inflammationEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleMedicine
The invention discloses bioactive nanoparticles composed of chitosan, poly-glutamic acid, and diethylenetriaminepentaacetic acid for use in radionuclide decorporation during radiological emergency. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8349799B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS20110142926A1Reduce resistanceEasy to transportPowder deliveryNervous disorderProtein insertionMedicine
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7867984B1Reduce inflammationEnhances intestinal epithelial barrier functionBiocidePowder deliveryNanoparticleAppetite suppressing
The invention discloses the bioactive nanoparticles composed of chitosan, poly-glutamic acid, and at least one appetite-suppressing agent characterized with a positive surface charge and a method of treating obesity in a subject in need via their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8038985B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of peptide drug and enzyme-inhibition compounds
InactiveUS20120121701A1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityAntibacterial agentsOrganic active ingredientsPeptide drugEnzyme inhibition
The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS7998459B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8236281B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityIn-vivo radioactive preparationsAmine active ingredientsDiabetes mellitusNanoparticle
The invention relates to a pharmaceutical composition of nanoparticles, wherein the nanoparticles comprise positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating diabetes of an animal subject.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8236752B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityBiocideAntimycoticsDiseaseNanoparticle
The invention relates to a method for treating disorders or diseases of a tight junction comprising delivering a pharmaceutical composition of nanoparticles to the tight junction, wherein the nanoparticles consist of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating said disorders or diseases of the tight junction of an animal subject.
Owner:NANOMEGA MEDICAL CORP